FDA Authorizes Tool For Duchenne Muscular Dystrophy Screening in Newborns
The FDA has granted marketing authorization for the GSP Neonatal Creatine Kinase-MM to aid physicians in screening newborns for Duchenne Muscular Dystrophy.
The FDA has granted marketing authorization for the GSP Neonatal Creatine Kinase-MM to aid physicians in screening newborns for Duchenne Muscular Dystrophy.
The rare disease report® condition center is a comprehensive resource for clinical news and expert insights on rare disease report®. Read more at HCPLive.
Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.
Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.
The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.
The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.
A year of research emphasizes the significance of collaboration, standardized approaches, and targeted therapies in rare pulmonary diseases.
Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug’s potential to address unmet needs within the hemophilia community.
Informed discussions about the pros and cons of different treatments help guide the decision-making process. When it comes to treatment adherence and overall quality of…
The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 – 49.2, while the Black population consistently…
Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for…